Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world

  • Nadia Melillo | nadiamelillo@yahoo.it Rheumatology Unit, Medical and Surgery Science Department, Riuniti Hospital, Foggia, Italy.
  • Francesco Paolo Cantatore Rheumatology Unit, Medical and Surgery Science Department, Riuniti Hospital, Foggia, Italy.

Abstract

Anti-hormonal therapies are used in the treatment of hormone dependent breast cancer. Their use may be complicated with the onset of arthralgia and autoimmune diseases. Recently a clinical relationship between oestrogen, anti-oestrogen therapy and rheumatic diseases has been reported in the literature, but, until now, experimental supporting data about the interacting biochemical pathways involved are still very limited. The understanding of this molecular link may provide important information to elucidate the relationship between autoimmunity and cancer mechanism and treatment. This review is intended to highlight the relationship between known common molecular mechanisms which explain this association and that probably need to be investigated in future studies.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Chen HH, Lin CH, Chen DY, et et al. Risk of major autoimmune diseases in female breast cancer patients: A nationwide, population-based cohort study.PLoS One. 2019 Sep 19;14(9) DOI: https://doi.org/10.1371/journal.pone.0222860

Tenti S, Giordano N, Cutolo M, et al. Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.Medicine(Baltimore). 2019 Mar;98(13). DOI: https://doi.org/10.1097/MD.0000000000015052

Schairer C, Pfeiffer RM, Gadalla SM.Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.Int J Cancer. 2018 Mar 15;142(6):1202-1208. DOI: https://doi.org/10.1002/ijc.31148

Valencia JC, Egbukichi N, Erwin-Cohen RA.Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.J Interferon Cytokine Res. 2019 Jan;39(1):72-84. DOI: https://doi.org/10.1089/jir.2018.0060

Kang YK, Jung SY, Qin J, et al.E2/Estrogen receptor/sjogren syndrome-associated autoantigen relieves coactivator activator-induced G1/S arrest to promote breast tumorigenicity.Mol Cell Biol. 2014 May;34(9):1670-81.

Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 2012;18(26):3831-52. DOI: https://doi.org/10.2174/138161212802083707

Toomer KH, Chen Z.Autoimmunity as a double agent in tumor killing and cancer promotion.Front Immunol. 2014 Mar 18;5:116. DOI: https://doi.org/10.3389/fimmu.2014.00116

Curigliano G.Immunity and autoimmunity: revising the concepts of response to breast cancer.Breast. 2011 Oct;20 Suppl 3:S71-4.

Roy LD, Sahraei M, Schettini JL, et al. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches.BMC Cancer. 2014 Mar 27;14:225.

Iwasa A, Arakaki R, Honma N, et al. Aromatase controls Sjögren syndrome-like lesions through monocyte chemotactic protein-1 in target organ and adipose tissue-associated macrophages.Am J Pathol. 2015 Jan;185(1):151-61.

Curigliano G.Immunity and autoimmunity: revising the concepts of response to breast cancer. Breast. 2011 Oct;20 Suppl 3:S71-4. DOI: https://doi.org/10.1016/S0960-9776(11)70298-3

Sofi GN, Sofi JN, Nadeem R, et al.Estrogen receptor and progesterone receptor status in breast cancer in relation to age, histological grade, size of lesion and lymph node involvement.sian Pac J Cancer Prev. 2012;13(10):5047-52. DOI: https://doi.org/10.7314/APJCP.2012.13.10.5047

Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of american pathologists guideline mrecommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Oncol Pract. 2010 Jul;6(4):195-7. DOI: https://doi.org/10.1200/JOP.777003

Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28, 2784–2795 (2010).

Manna PR, Molehin D, Ahmed AU.Dysregulation of Aromatase in Breast, Endometrial, and Ovarian Cancers: An Overview of Therapeutic Strategies.Prog Mol Biol Transl Sci.2016;144:487-537. DOI: https://doi.org/10.1016/bs.pmbts.2016.10.002

Kinoshita Y, Chen S.Induction of aromatase (CYP19) expression in breast cancer cells through a

nongenomic action of estrogen receptor alpha.Cancer Res. 2003 Jul 1;63(13):3546-55.

Lumachi F, Santeufemia DA, Basso SM.Current medical treatment of estrogen receptor-positive breast cancer.World J Biol Chem. 2015 Aug 26;6(3):231-9. DOI: https://doi.org/10.4331/wjbc.v6.i3.231

Lumachi F, Brunello A, Maruzzo M, et al.Treatment of estrogen receptor-positive breast cancer.Curr Med Chem. 2013;20(5):596-604. DOI: https://doi.org/10.2174/092986713804999303

Ziv E, Tice JA, Sprague B, et al.Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.PLoS One. 2017 Jan 20;12(1) DOI: https://doi.org/10.1371/journal.pone.0168601

Cutolo M, Capellino S, Sulli A, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006 Nov;1089:538-47. DOI: https://doi.org/10.1196/annals.1386.043

Benagiano M, Bianchi P, D'Elios MM, Brosens Iet al.Autoimmune diseases: Role of steroid hormones. Best Pract Res Clin Obstet Gynaecol. 2019 Mar 16. DOI: https://doi.org/10.1016/j.bpobgyn.2019.03.001

Singer O, Cigler T, Moore AB, et al. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.Arthritis Care Res (Hoboken). 2012 Dec;64(12):1910-8. DOI: https://doi.org/10.1002/acr.21756

Crew KD, Greenlee H, Capodice J,et al. Prevalence of joint symptoms in postmenopausal

women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007 Sep 1;25(25):3877-83 DOI: https://doi.org/10.1200/JCO.2007.10.7573

Horimoto Y, Sauto M, Kasumi F, Arthralgia in 329 patients taking aromatase inhibitors. Breast Care 2009; 4:319323. DOI: https://doi.org/10.1159/000236050

Laroche M, Borg S, Lassoued S, De Lafontan B, Roché H. Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome. J Rheumatol. 2007 Nov;34(11):2259-63.

Caprioli M, Carrara G, Sakellariou G, et al. Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology.RMD Open. 2017 Sep 28;3(2) DOI: https://doi.org/10.1136/rmdopen-2017-000523

Scarpa R, Atteno M, Peluso R, et al. Rheumatic complaints in women taking aromatase inhibitors for treatment of hormone-dependent breast cancer. J Clin Rheumatol 2011;17:169-72. DOI: https://doi.org/10.1097/RHU.0b013e31821bfc48

Pokhai G, Buzzola R, Abrudescu A. Letrozole-induced very early systemic sclerosis in a patient with breast cancer: a case report. Arch Rheumatol 2014;29:126-9. DOI: https://doi.org/10.5606/ArchRheumatol.2014.3429

Pathmarajah P, Shah K, Taghipour K, et al.Letrozole-induced necrotising leukocytoclastic small vessel vasculitis: First report of a case in the UK.Int J Surg Case Rep. 2015;16:77-80. DOI: https://doi.org/10.1016/j.ijscr.2015.09.024

Chen JY, Ballou SP.The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.J Rheumatol. 2015 Jan;42(1):55-9. DOI: https://doi.org/10.3899/jrheum.140367

Cowppli-Bony A, Trétarre B, Marrer E, et al.Compliance with clinical guidelines for breast cancer management: A population-based study of quality-of-care indicators in France.PLoS One. 2019 Oct 23;14(10). DOI: https://doi.org/10.1371/journal.pone.0224275

Laroche F, Perrot S, Medkour T, Cottu PH, et al. Quality of life and impact of pain in women treated with aromatase inhibitors for breast cancer. A multicenter cohort study. PLoS One. 2017 Nov 8;12(11) DOI: https://doi.org/10.1371/journal.pone.0187165

Blomqvist A.Sex hormones and pain: a new role for brain aromatase?J Comp Neurol. 2000 Aug 7;423(4):549-51. DOI: https://doi.org/10.1002/1096-9861(20000807)423:4<549::AID-CNE1>3.0.CO;2-B

Hill, R.A., Chua, H.K., Jones, M.E., et al Estrogen deficiency results in apoptosis in the frontal cortex of adult female aromatase knockout mice. Mol Cell Neurosci. 2009; 41: 1–7 DOI: https://doi.org/10.1016/j.mcn.2008.12.009

Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol. 2001 May 15;19(10):2767.

Martens HA, Schröder CP, van der Eerden PJ, et al. Severe disabling tendinopathy caused by anastrazole. Rheumatology (Oxford) 2007 Oct; 46(10):1619-21. DOI: https://doi.org/10.1093/rheumatology/kem213

Bauml J, Chen L, Chen J, et al. Arthralgia among women taking aromatase inhibitors: is there a shared inflammatory mechanism with co-morbid fatigue and insomnia? Breast Cancer Res. 2015; 17(1):89. DOI: https://doi.org/10.1186/s13058-015-0599-7

Mao J.J, Su H.I., Feng R., et al. Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Breast Cancer Res Treat 2011;13(1). DOI: https://doi.org/10.1186/bcr2813

Genetic variation in CYP19A1 and interleukin-6 and aromatase inhibitor-associated arthralgia in breast cancer survivors.

Capellino S, Straub RH, Cutolo M.Aromatase and regulation of the estrogen-to-androgen ratio in synovial tissue inflammation: common pathway in both sexes.Ann N Y Acad Sci. 2014 May;1317:24-31. DOI: https://doi.org/10.1111/nyas.12398

Le Bail J, Liagre B, Vergne P, et al.Aromatase in synovial cells from postmenopausal women.Steroids. 2001 Oct;66(10):749-57. DOI: https://doi.org/10.1016/S0039-128X(01)00104-0

Wang J, Zhang Q, Jin S, et al. Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis.Exp Gerontol. 2009 Jun-Jul;44(6-7):398-405. DOI: https://doi.org/10.1016/j.exger.2009.03.003

Kiyomi A, Makita M, Iwase T, et al.Clinical Significance of Female-hormones and Cytokines in Breast Cancer Patients Complicated with Aromatase Inhibitor-related Osteoarthropathy - Efficacy of Vitamin E. J Cancer. 2015 Feb 25;6(4):367-76. DOI: https://doi.org/10.7150/jca.10695

Purohit A, Ghilchik MW, Duncan L, et al.Aromatase activity and interleukin-6 production by normal and malignant breast tissues.J Clin Endocrinol Metab. 1995 Oct;80(10):3052-8. DOI: https://doi.org/10.1210/jcem.80.10.7559896

Abana CO, Bingham BS, Cho JH, Graves AJ, et al. IL-6 variant is associated with metastasis in breast cancer patients.PLoS One. 2017 Jul 21;12(7):e0181725. DOI: https://doi.org/10.1371/journal.pone.0181725

Lee JH, Kim JY, Kim CH. A Case of Bilateral Trigger Thumbs Secondary to Aromatase Inhibitor. Med J. 2015 Jul;56(4):1167-9. DOI: https://doi.org/10.3349/ymj.2015.56.4.1167

Loeffler BJ, Gaston RG.Aromatase inhibitors and their side effects: what hand surgeons should know. Hand Surg Am. 2010 Jul;35(7):1206-8. DOI: https://doi.org/10.1016/j.jhsa.2009.12.010

Morales L, Pans S, Paridaens R, et al. Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging.Breast Cancer Res Treat. 2007 Jul;104(1):87-91. DOI: https://doi.org/10.1007/s10549-006-9394-6

Zabotti A, Idolazzi L, Batticciotto A, et al. Enthesitis of the hands in psoriatic arthritis: an ultrasonographic perspective.Med Ultrason. 2017 Nov 29;19(4):438-443. DOI: https://doi.org/10.11152/mu-1172

Watad A, Cuthbert RJ, Amital H, et al. Enthesitis: Much More Than Focal Insertion Point Inflammation.Curr Rheumatol Rep. 2018 May 30;20(7):41. DOI: https://doi.org/10.1007/s11926-018-0751-3

Gravallese EM, Schett G.Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis.Nat Rev Rheumatol. 2018 Nov;14(11):631-640. DOI: https://doi.org/10.1038/s41584-018-0091-8

Roy LD, Sahraei M, Schettini JL, Gruber HE, et al. Systemic neutralization of IL-17A significantly reduces breast cancer associated metastasis in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;14:225. DOI: https://doi.org/10.1186/1471-2407-14-225

Laroche M, Borg S, Lassoued S, De Lafontan B, et al. Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol. 2007;34(11):2259–2263.

Yasar Bilge NS, Korkmaz C.Does Aromatase Inhibitors Cause Sjogren's Syndrome and Polyneuropathy? World J Oncol. 2014 Aug;5(4):181-182. DOI: https://doi.org/10.14740/wjon695w

Jones ME, Thorburn AW, Britt KL, et al.Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity.Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12735-40 DOI: https://doi.org/10.1073/pnas.97.23.12735

Shim GJ, Warner M, Kim HJ, Andersson S, et al.Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren's syndrome. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12628-33. DOI: https://doi.org/10.1073/pnas.0405099101

Iwasa A, Arakaki R, Honma N, et al. Aromatase controls Sjögren syndrome-like lesions through monocyte chemotacticprotein-1 in target organ and adipose tissue-associated macrophages.Am J Pathol. 2015 Jan;185(1):151-61. DOI: https://doi.org/10.1016/j.ajpath.2014.09.006

Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem. Biophys. Res. Commun 2006. 339:415–421. DOI: https://doi.org/10.1016/j.bbrc.2005.11.029

McEwan WA, Tam JC, Watkinson RE, Bidgood SR, et al. Intracellular antibody-bound pathogens stimulate immune signaling via the Fc receptor TRIM21. Nat Immunol. 2013 Apr;14(4):327-36 DOI: https://doi.org/10.1038/ni.2548

Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in female cancers.Gynecol. Oncol. 2012.127:180–185. DOI: https://doi.org/10.1016/j.ygyno.2012.07.100

Kang YK, Jung SY, Qin J, et al. E2/Estrogen receptor/sjogren syndrome-associated autoantigen relieves coactivator activator-induced G1/S arrest to promote breast tumorigenicity. Mol Cell Biol. 2014 May;34(9):1670-81. DOI: https://doi.org/10.1128/MCB.01564-13

Yoshimi R, Ishigatsubo Y, Ozato K. Autoantigen TRIM21/Ro52 as a Possible Target for Treatment of Systemic Lupus Erythematosus. Int J Rheumatol.2012;2012:718237 DOI: https://doi.org/10.1155/2012/718237

Zhou W, Zhang Y, Zhong C, et al. Decreased expression of TRIM21 indicates unfavorable outcome and promotes cell growth in breast cancer. Cancer Manag Res. 2018 Sep 20;10:3687-3696. DOI: https://doi.org/10.2147/CMAR.S175470

Itou J, Li W, Ito S, et al.Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif-containing 21.J Biol Chem. 2018 Apr 27;293(17):6556-6564. DOI: https://doi.org/10.1074/jbc.RA117.000245

Moxley G. Rheumatic disorders and functional disability with aromatase inhibitor therapy. Clin Breast Cancer. 2010 Apr;10(2):144-7. DOI: https://doi.org/10.3816/CBC.2010.n.019

Wendling D, Letho-Gyselinck H, Guillot X, et al. Arthralgia and aromatase inhibitors. Joint Bone Spine 2014;81:187–8. DOI: https://doi.org/10.1016/j.jbspin.2013.06.011

Perry RR, Kang Y, Greaves BR.Relationship between tamoxifen-induced transforming growth factor beta 1 expression, cytostasis and apoptosis in human breast cancer cells.Br J Cancer. 1995 Dec;72(6):1441-6. DOI: https://doi.org/10.1038/bjc.1995.527

Younus J, Kligman L.Management of aromatase inhibitor-induced arthralgia.Curr Oncol. 2010 Feb;17(1):87-90. DOI: https://doi.org/10.3747/co.v17i1.474

Published
2020-04-01
Info
Issue
Section
Reviews
Keywords:
Breast cancer, rheumatic diseases, anti-hormonal therapy, aromatase inhibitors.
Statistics
  • Abstract views: 437

  • PDF: 149
  • HTML: 0
How to Cite
Melillo, N., & Cantatore, F. P. (2020). Breast cancer anti-hormonal therapy and rheumatic diseases: linking the clinical to molecular world. Beyond Rheumatology, 2(1), 14-19. https://doi.org/10.4081/br.2020.30